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O6-methylguanine-DNA-methyltransferase
immunostaining intensity in glioblastoma







a b s t r a c t
Immunohistochemistry (IHC) for O6-methylguanine-DNA-methyltransferase (MGMT) has
shown heterogeneous results. Cell staining intensity has not been included as a quantiﬁable
variable in IHC analyses. We performed MGMT IHC in 29 patients diagnosed as glioblastoma
classifying cells into three categories based on nuclear staining intensity compared with
adjacent endothelium. The median proportions of strong-moderate, weak and no staining
cells were 10%, 16% and 71%, respectively. The proportion of positive cases for MGMT
expression varies from 38% to 52% depending on the classiﬁcation of weakly stained cells.
This letter challenges previous studies that have not included intensity as a variable for IHC
analysis.
© 2017 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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Even though tremendous advances in the molecular and
clinical characterization of glioblastoma (GBM) reached during
the last decade, 5-year survival remains limited to 5% [1] and
median survival with the current standard treatment is 14.6
months [2]. Nevertheless, median survival can vary from 12.7
to 21.7 months depending on the O6-methylguanine-DNA-
methyltransferase (MGMT) promoter methylation status [3],
one of the more powerful genetic prognosticator of response to
alkylating agent therapy in malignant gliomas [4]. To date,
genetic testing has not become a routine investigation and the
discordances between different techniques to analyze MGMT
and clinical outcomes have promoted an interest on method-
ological sources of variability.
MGMT gene (10q26) codiﬁes a reparative enzyme that
removes methyl groups from DNA. The MGMT cytosine-
guanine (CpG) island promoter methylation leads to the partial
or complete gene silencing [5] that has been associated with
better response to alkylating chemotherapy [3]. Despite many
testing methods have been proposed, MGMT promoter testing
still present many obstacles and has not become a routine
investigation in GBM [6]. Although Methylation-speciﬁc
polymerase chain reaction (MSP) and sequencing methodsare well established techniques, they are expensive and not
always available in general hospitals.
Immunohistochemistry (IHC) is a fast and less expensive
method than promoter analyses. However, the association
between MGMT protein expression and clinical outcome
remains controversial [6,7]. Observer variability, non-stan-
dardized cut-off point to deﬁne MGMT positivity and the lack
of methods to exclude normal cells expressing MGMT have
been pointed as sources of variability in IHC results [7].
However, the evaluation of staining intensity has not been
included as parameter for IHC analyses in most of previous
studies. Although a global score of intensity has been proposed
[8], the proportion and impact of different patterns of cell
staining intensities in the same IHC ﬁeld of analyses is not
known. We present our preliminary observations using a
method for MGMT IHC analyses that includes cell staining
intensity as a quantitative variable.
This study was performed with the Institutional Review
Board approval and ethical approval. A convenience sample
of 30 patients diagnosed as glioblastoma during 2013 and
2014 in the Institute of Neurosurgery Dr. Alfonso Asenjo in
Santiago of Chile was selected. Two cases were considered
secondary glioblastoma with the previous histological diagno-
sis of diffuse ﬁbrillary astrocytoma (grade II) and anaplastic
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patients was 54.8 years (ranging from 34 to 72) and 12 (40%)
were women. Presence of suitable tumor tissue in parafﬁn-
embedded blocks was conﬁrmed by hematoxylin eosin
staining before immunohistochemistry procedures. MGMT
IHC was performed following the avidin/biotin-based perox-
ydase system (VECTASTAIN® Elite ABC HRP kit, Peroxidase
Universal) using a monoclonal mouse anti-MGMT antibody
(MT3.1, ab39253; Abcam) in a dilution deﬁned by titration test
(1:25). All tissues were counterstained with hematoxylin to
visualize non MGMT stained cells. Four high magniﬁcation
ﬁelds (400) from each case were selected for analyses
excluding areas close to edges and necrosis to avoid false
positives. Visual assessment was performed using a multistep
algorithm and non-tumor cells expressing MGMT, including
endothelium and lymphocytes were visually excluded based
on histological features. Cells were classiﬁed in three catego-
ries based on nuclear staining intensity compared with
adjacent endothelium (Fig. 1A): strong-moderate (similar or
stronger than endothelium), weak (heterogeneous or weaker
than endothelium) and no staining. We chose 10% as cut-off
because it has been used in most previous studies [7].
However, the cut-off point to allocate a case as positive ranges
from 5 to 35% and remain largely arbitrary [7].
We obtained results of 29 cases because the quality of one
sample impeded an adequate staining. The hematoxylin eosin
staining conﬁrmed the presence of tumor tissue fulﬁlling the
World Health Organization (WHO) criteria for glioblastoma in
all cases. In the MGMT immunohistochemistry analysis, the
median number of cells counted per case was 692 (interquartile
range [IQR] 494–928). The median proportions of strong-
moderate, weak and no staining cells were 10% (IQR 4–24%),
16% (IQR 10–26%) and 71% (IQR 52–85%), respectively (Fig. 1B).
Excluding weak staining cells from positive cells group and
using 10% as the cut-off we classiﬁed 15 (52%) as positive for
MGMT expression. However, when we include all stained cells
as positives regardless intensity, 11 (38%) negative cases ac-
cording to the ﬁrst criteria are classiﬁed as positive (Fig. 1C).
This is the ﬁrst study reporting cell counting by predeﬁned
categories based on nuclear staining intensity criteria. Our
preliminary observation of a variety of intensity patterns in aFig. 1 – (A) Examples of the staining intensity categories used for i
methyltransferase (MGMT) and hematoxilyn in glioblastoma (400
and reference of moderate MGMT staining intensity; (b) tumor c
tumor cell with weak nuclear staining intensity; (d) negative MGM
percentage of cells corresponding to each staining intensity cate
percentage are presented for each category. (C) Diagnosis of MG
11 cases (MGMT+/S) diagnosis depends on the inclusion or exclsame ﬁeld of observation emphasizes the importance of
include a quantiﬁable measure of cell staining intensity in
MGMT IHC analyses. Although an intensity score has been
previously proposed [8], this method is based on a global case
scoring rather than a cell by cell classiﬁcation system as we
did. The method that we propose challenges the results from
previous studies that have not reported a criterion to deal with
different staining intensities in IHC for MGMT analyses.
We assessed the effect of the weakly stained cells – that
represented 16% (IQR 10–26%) of all counted cells – on the case
diagnosis of MGMT expression. Using 10% as cut-off to deﬁne a
positive MGMT expression status, the proportion of positive
MGMT expression cases varied from 52% to 90% depending on
the classiﬁcation of weak staining cells and the cut-off chosen.
In this study, we have not tested MGMT promoter status and
most of the patients in our sample did not receive alkylating
chemotherapy. Despite these limitations to establish the
prognostic value of our results, this change, the variation on
the expression diagnosis highlights the unrecognized role of
intensity as a source of heterogeneity in IHC results. Moreover,
this potential improvement on the reproducibility and reli-
ability of the ICH analysis can contribute to determine an ideal
cut-off point for future studies. Since the clinical signiﬁcance
of every improvement in IHC procedure must be carefully
tested, our next step will be to correlate this IHC analysis with
the MGMT promoter status and clinical outcomes.
Although genetic testing for MGMT promoter status has
been used in most of studies linking MGMT and response to
chemotherapy, it has not become a routine investigation in
GBM. Moreover, comparative studies have shown that promot-
er status is not a gold standard, with the combined study of
MGMT including the assessment of protein expression levels
resulting in the best predictive value [9]. For that reason,
quantifying of tumor cells by staining intensity could contrib-
ute to a better understanding of the underlying mechanisms of
discordances between promoter methylation, protein expres-
sion and clinical outcome shown in previous studies [7,9]. Our
strategy is in keeping with the necessity to elucidate the role of
methylation independent pathways for MGMT expression that
could explain the discordances between promoter methylation
and mRNA expression [10]. Finally, our method may help tommunohistochemistry analyses of O6-methylguanine-DNA-
T): (a) MGMT positive endothelium used as positive control
ell with a strong-moderate nuclear staining intensity; (c)
T staining cell. Scale bar 10 mm (B) Scatter plot showing the
gory for each case. The median and interquartile range of
MT expression by immunohistochemistry in 29 cases. In
usion of the weak staining intensity cells group.
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and IDH1 gene mutations on the overall survival in chemor-
adiotherapy-treated patients [11]. However, further studies
should be testing these hypotheses.
In conclusion, our preliminary results show that different
staining intensity cells can be identiﬁed in the same tissue
sample and the weak staining intensity cells group can be
quantiﬁed to estimate its impact on the diagnosis of MGMT
expression. Since the intensity of MGMT staining is a missed
variable in most previous studies, this report is an alert for
neuropathology groups working on MGMT immunohis-
tochemistry regarding the relevance of reporting the propor-
tion of weakly stained cells in future research.
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